相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
Zachary S. Morris et al.
CANCER RESEARCH (2016)
Harnessing the immune system for the treatment of melanoma: current status and future prospects
Andrea Guennoun et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Andreas Lundqvist et al.
Journal for ImmunoTherapy of Cancer (2016)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Immune Checkpoint Blockade and Interferon-α in Melanoma
Imran Rafique et al.
SEMINARS IN ONCOLOGY (2015)
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Mark R. Albertini et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
Jacquelyn A. Hank et al.
CLINICAL CANCER RESEARCH (2009)
Monoclonal antibodies in therapy of solid tumors
David M. Heimann et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2007)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy
ZC Neal et al.
CLINICAL CANCER RESEARCH (2004)
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
DM King et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
